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Received 30 December 2009; received in revised form 10 February 2010; accepted 10 February 2010Abstract To improve proarrhythmic predictability of preclinical models, we assessed whether human ventricular-like
embryonic stem cell-derived cardiomyocytes (hESC-CMs) can be selected following a standardized protocol. Also, we
quantified their arrhythmogenic response and compared this to a contemporary used rabbit Purkinje fiber (PF) model. Multiple
transmembrane action potentials (AP) were recorded from 164 hESC-CM clusters (9 different batches), and 12 isolated PFs
from New Zealand White rabbits. AP duration (APD), early afterdepolarizations (EADs), triangulation (T), and short-term
variability of repolarization (STV) were determined on application of the IKr blocker E-4031 (0.03/0.1/0.3/1 μM). Isoproterenol
(0.1 μM) was used to assess adrenergic response. To validate the phenotype, RNA isolated from atrial- and ventricular-like
clusters (n=8) was analyzed using low-density Taqman arrays. Based on initial experiments, slow beating rate (b50 bpm) and
long APD (N200 ms) were used to select 31 ventricular-like clusters. E-4031 (1 μM) prolonged APD (31/31) and induced EADs
only in clusters with APD90N300 ms (11/16). EADs were associated with increased T (1.6±0.2 vs 2.0±0.3⁎) and STV (2.7±1.5 vs
6.9± 1.9⁎). Rabbit PF reacted in a similar way with regards to EADs (5/12), increased T (1.3±0.1 vs 1.9±0.4⁎), and STV
(1.2±0.9 vs 7.1±5.6⁎). According to ROC values, hESC-CMs (STV 0.91) could predict EADs at least equivalent to PF (STV 0.69).
Isoproterenol shortened APD and completely suppressed EADs. Gene expression analysis revealed that HCN1/2, KCNA5, and
GJA5 were higher⁎ in atrial/nodal-like cells, whereas KCNJ2 and SCN1B were higher⁎ in ventricular-like cells (⁎Pb0.05).
Selection of hESC-CM clusters with a ventricular-like phenotype can be standardized. The proarrhythmic results are
qualitatively and quantitatively comparable between hESC-CMs and rabbit PF. Our results indicate that additional validation of
this new safety pharmacology model is warranted.
© 2010 Elsevier B.V. All rights reserved.Abbreviations: APD, action potential duration; BVR, beat-to-beat variability of repolarization; EAD, early afterdepolarization; hESC-CM,
human embryonic stem cell-derived cardiomyocyte; PF, Purkinje fiber; ROC, receiver-operated characteristics; STV, short-term variability of
repolarization; TAP, transmembrane action potential.
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Human stem cells as a tool in drug discovery represent a fairly
new concept which is based on the hypothesis that cells of
human origin may help bridge the gap between preclinical
research and clinical trials. The fact that contemporary
preclinical models sometimes fail to predict efficacy and
safety of new compounds is one reason why the pharmaceu-
tical industry suffers from high attrition rates (Kola and
Landis, 2004). Human embryonic stem cell-derived cardio-
myocytes (hESC-CMs) may potentially contribute to drug
discovery at several stages, including target validation,
screening, and safety pharmacology (He et al., 2007; Jonsson
et al., 2009). Advantages of hESC-CMs over currently used
animalmodels include their human origin, likelymaking them
more representative for the human situation, and the close to
unlimited supply of cells that survive in culture for several
weeks. Additionally, the use of in vitro cultured stem cells,
and their derivatives, may help to reduce the number of
laboratory animals needed during early drug development.
In the preclinical setting, most safety pharmacologists
apply three strategies to define the proarrhythmic risk of
new compounds: (1) the hERG current is measured in cell
lines, (2) action potentials (APs) are recorded from a
multicellular preparation like the Purkinje fiber (PF), or
from single ventricular myocytes (mostly rabbit) to deter-
mine the effect on the duration of the AP (APD) and to record
an arrhythmic endpoint, e.g., early afterdepolarizations
(EADs), and (3) an ECG is recorded in conscious animals to
determine any effects of the drug on the QT interval (Jonsson
et al., 2009). It appears that hESC-CMs are suited to replace
the APD-EAD recordings in isolated animal tissue.
Recordings of at least three different types of APs were
reported using clusters of hESC-CM and sharp microelec-
trodes (He et al., 2003; Zhang et al., 2009). Similar results,
indicating nodal-like, atrial-like, and ventricular-like AP,
were reported using patch-clamp recordings on isolated cells
(Mummery et al., 2003). Patch-clamp recordings have also
verified the existence and relevance of major ion currents
such as Na+, Ca2+, and K+ currents for the generation of APs in
hESC-CMs. In addition, these currents in hESC-CMs could
be manipulated by specific ion-channel blockers and
expression of the subunits forming the ion channels involved
was verified (Sartiani et al., 2007; Satin et al., 2004; Wang
et al., 2005; Zhang et al., 2003). These results show that
hESC-CMs are capable of forming the three major types ofTable 1 Basic characterization of hESC-CM clusters
f (bpm) APD50 (ms)
Ventricular-like
n=42 81±31⁎ 147±37⁎
Atrial-like
n=54 151±40 70±15
Nodal-like
n=18 130±47 58±16
Based on AP characteristics, hESC-CM clusters were divided into three gr
longer APD50 and APD90 (Pb0.001) compared to atrial- or nodal-like ce
lower upstroke velocity (Vmax, Pb0.01) than atrial-like cells. All three p
most prominent in nodal-like cells. f, beating frequency; bpm, beats p
repolarization; Amp, AP amplitude; Vmax, maximum rate of depolarizaCMs found in the heart. Although a great advantage, this
can also become a hurdle since the differentiation often
leads to very heterogeneous cell populations. For safety
pharmacology, particularly cells with a ventricular-like
phenotype are of interest; thus selection of this type of CM
is crucial.
The proarrhythmic potential of hESC-CMs has been
illustrated through application of the IKr blocker E-4031,
which on administration caused EADs (He et al., 2003; Caspi
et al., 2009). However, besides scattered examples of EAD
provocation, only one previous study touches on any
arrhythmogenic quantification (He et al., 2003). Notably,
none of the previous studies provide information on stan-
dardization; meaning an overview of the critical cellular
parameters necessary to achieve the reported results (e.g.,
selection criteria for ventricular-like CMs, failures and
successes, problems, or improvements). Additionally, a
comparison with existing screening models, such as rabbit
PF, and information concerning suggested alternative
arrhythmogenic parameters, such as TRIaD (Hondeghem,
2005; Hondeghem et al., 2001) (Triangulation, Reverse use
dependence, Instability, and Dispersion of ventricular
repolarization), or beat-to-beat variability of repolarization
(BVR) (Thomsen et al., 2004), are lacking.
In this study, we have investigated the proarrhythmic
potential of hESC-CMs, with emphasis on selection, standard-
ization, and quantification. The results were compared to data
obtained from the isolated rabbit PF model, using occurrence
of EADs as the final endpoint. Our data support the conclusion
that it is possible to select hESC-CM clusters with a ventricular-
like phenotype, and that the proarrhythmic results obtained
using these clusters qualitatively and quantitatively are
comparable to those obtained with rabbit PF. The molecular
templates that give rise to the various phenotypes of the hESC-
CM clusters were identified by upregulation of either atrial/
nodal- or ventricular specific genes.
Results
Electrophysiological characterization of hESC-CM
clusters
Basic characterization
In a first set of experiments, transmembrane action
potential (TAP) recordings were carried out using 114 hESC-APD90 (ms) Amp (mV) Vmax (V/s)
220±51⁎ 61±17 14±9
115±20 69±14 21±13
99±19 53±14⁎ 11±9⁎
oups. Ventricle-like cells had a lower beating rate (f, Pb0.001) and
lls. Nodal-like cells had a smaller AP amplitude (Amp, Pb0.001) and
henotypes showed a slow phase 4 depolarization, although this was
er minute; APD50/APD90, action potential duration at 50/90%
tion.
Figure 1 (a) TAP recordings in hESC-CM clusters showed typical examples of ventricle-like (top), atrial-like (middle), and nodal-like (bottom) APs. In many cases, the phenotype could
be determined based solely on APmorphology with ventricle-like cells showing a more pronounced plateau phase (and thereby longer APD) compared to both atrial- and nodal-like cells.
The distinction made between atrial- and nodal-like cells is less pronounced and should be interpreted with caution, but is mainly due to differences in amplitude and Vmax. (b) Control
AP recording from a ventricular-like cluster (top) and typical generation of EADs in a hESC-CM cluster after administration of E-4031 (1 μM) (middle and bottom).
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192 M.K.B. Jonsson et al.CM clusters and the AP shapes and properties were
evaluated. A clear heterogeneity between clusters was
observed, which allowed grouping of phenotypes into three
major types: ventricular-like, atrial-like, or nodal-like
(Table 1 and Fig. 1a). Importantly, repeated recordings
at various locations within one cluster showed that each
cluster was characterized by one predominant AP mor-
phology (see Supplemental Fig. 1). Ventricular-like APs had
a significantly longer AP duration (both APD50 and APD90)
compared to atrial-like or nodal-like APs (Pb0.001), and
they displayed a pronounced plateau phase (Table 1 and
Fig. 1a). The clusters containing ventricular-like CMs also
had a lower beating frequency than atrial- or nodal-like
clusters (Pb0.001), and could often be selected based
solely on this criterion (Fig. 2). Nodal-like APs were
discriminated from atrial-like APs by a prominent phase 4
depolarization, but more specifically by a significantly
lower upstroke velocity (Pb0.01) and a smaller amplitude
(Pb0.001, Table 1). The data indicate that hESC-CMs are
not yet as mature as CMs from the human heart, since the
APD is shorter than expected, the upstroke velocity is
slower, and the amplitude is lower. However, examples of
clusters showing a much more mature phenotype than the
average were occasionally observed, indicating that, the in
vitro developed hESC-CMs have the capacity to reach a
phenotype close to native ventricular CMs.
Arrhythmic testing
In a second set of experiments, we used the above
findings to select an additional 31 ventricular-like clusters
(from a total of 50 clusters) to investigate the occurrence of
EADs under the influence of the known IKr blocker E-4031.
The initial selection criterion for ventricular-like clusters
was a beating frequency below 50 bpm. Once recordings
were initiated, APD90 proved to be a second selection
criterion. Fig. 2 illustrates how the spontaneous beating
frequency of an individual cell cluster corresponded to the
AP duration recorded from that cluster. It should be noted
that all AP recordings were performed at 1 Hz; thus the
longer APD90 seen at lower bpm is not due to a lower beating
rate (the beating rate on the x-axis was measured before
electrical pacing and recordings were started (R2=0.512,
F=24.125, Pb0.001).Figure 2 Graph showing APD90 (y-axis) at 1 Hz in relation to
pre-experimental beating rate in hESC-CM clusters. There is a
significant inverse relation between these parameters
(R2=0.512, F=24.125, Pb0.001).APD prolongation and EADs in response to E-4031
E-4031 is known to specifically block the IKr current
conducted by hERG channels. Blockade of those voltage-
gated K+ channels reduces repolarization strength, prolongs
APD, and induces EADs (Lee et al., 1993). From the basic
characterization of the hESC-CMs, the mean APD90 of the
ventricular-like cells was 220±51 ms (see Table 1), hence,
for E-4031 experiments, cells with an APD90N200 ms were
selected (31/50 clusters). The remaining 19 clusters had an
APD90b200 ms. Four different concentrations (0.03, 0.1,
0.3, and 1.0 μM) of E-4031 increased the APD90, although
only the two highest concentrations reached statistical
significance (Fig. 3a, left panel). When administering 1 μM
E-4031, 11 clusters showed EADs with or without interruption
of pacing (Table 2 and Fig. 1b). All of these 11 clusters had a
control APD90N300 ms (with a mean APD90 of 365±48 ms).
None of the clusters b200 ms (n=19) or between 200 and
300 ms (n=15) showed EADs on incubation with E-4031. No
EADs were detected under control conditions, not even with
beating rates lower than 1 Hz or after interrupted pacing. A
reverse frequency-dependent response of APD90 to E-4031
was also detected, with a more pronounced drug effect at
1 Hz pacing (+36.2%) compared to 2 Hz (+14.3%) (Fig. 3a,
right panel).
Triangulation and beat-to-beat variability
As the APD increased with E-4031, an increased triangu-
lation of the AP from 1.6±0.2 during control to 2.0±0.3 prior
to EAD formation was detected (Pb0.001, Table 2, Fig. 3b).
In addition, short-term variability of repolarization (STV), as
a predictor of BVR, was analyzed before and after adminis-
tration of E-4031. During control conditions, a longer APD
was correlated with a higher STV. For hESC-CMs with an
APD90N300 ms the STV was 2.7±1.5 (Table 2). After E-4031
administration, a significant increase in STV (6.9±1.9,
Pb0.01) was observed for cells that subsequently showed
EADs. In clusters where no EADs occurred, an increase in STV
(3.9±2.2, Pb0.05) was also seen but this was significantly
lower than when EADs did occur (Pb0.05). Triangulation and
STV were calculated immediately prior to formation of the
first EAD or when the steady state was reached (incase no
EADs occurred). Fig. 3c illustrates STV in a Poincare plot for a
typical cluster that did not generate EADs (left panel), and
for one where EADs subsequently occurred (right panel).
Adrenergic response
As previously reported, hESC-CMs respond to adrenergic
stimulation (Norstrom et al., 2006). In this study, isoproter-
enol (0.1 μM) increased the beating frequency and shortened
the APD. When administered after E-4031 superfusion,
isoproterenol rapidly shortened the APD (Fig. 3a, left
panel, n=5) and completely suppressed EADs.
Comparison of hESC-CMs and rabbit PF
All data collected from experiments with both hESC-CMs and
PF were performed at the same lab, using the same
experimental setup, and under the same conditions (i.e.,
pacing at 1 or 2 Hz and administration of 1 μM E-4031). Since
only hESC-CMs with a control APD90N300 ms displayed EADs
on administration of E-4031, these were considered as
Figure 3 Effect of E-4031 on ventricular-like hESC-CM clusters. (a) Change in APD90 at 0.03, 0.1, 0.3, and 1.0 μM E-4031, followed
by administration of 100 nM isoproterenol (iso, left panel). The two highest concentrations caused significant prolongation of the AP
(Pb0.01 for 0.3 μM, Pb0.001 for 1.0 μM, n=5), which was reversed by isoproterenol (Pb0.001). A 1 μM E-4031 caused prolongation of
the AP at 1 Hz (P=0.001, n=10) and 2 Hz (P=0.004, n=4), but significantly (P=0.01) more at 1 Hz, indicating reverse use dependence
(right panel). (b) APD prolonged predominantly due to a decrease in late repolarization rate. At 1 Hz, a greater effect was seen at
APD90 (P=0.0003, n=9) than at APD50, resulting in increased triangulation (left panel). (c) Poincare plots showing an increase in
APD90 after E-4031 administration. In cases where no EADs developed, STV remained low (left panel). Prior to EAD formation,
however, an increase in STV was seen (right panel).
193Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytesventricular-like and were included in the comparison with
PF. E-4031 induced APD prolongation and triangulation,
increased STV, and provoked EADs in both hESC-CMs and
rabbit PF (data collected in Table 2).
The APD90 in PF was significantly shorter than in
selected hESC-CMs (APD90N300 ms) under baseline condi-
tions (246±30 vs 365±48 ms, Pb0.05). As compared to
hESC-CM, APD90 experienced a greater lengthening as a
result of IKr block in PF (+137% vs +30%). The reverse
frequency-dependent response observed after E-4031 ad-
ministration in hESC-CMs (61% less APD prolongation at 2 Hz
compared to 1 Hz) was comparable to rabbit PF (80±19 vs145±46% prolongation which means 45% less APD prolon-
gation at 2 Hz compared to 1 Hz, P=0.002).
At baseline, triangulation was significantly higher for
hESC-CMs (ratio 1.6±0.2) than PF (ratio 1.3±0.1). A
significant increase was seen for both models during
exposure to E-4031 and they eventually reached similar
values (2.0±0.3 vs 1.9±0.4, respectively). The same was
observed for BVR, where STV was significantly lower in PF
than hESC-CMs at baseline (2.7±1.5 vs 1.2±0.9, Pb0.05),
but an almost 6-fold increase for PF and a 2.5-fold increase
for hESC-CMs resulted in comparable STV values prior to EAD
formation (7.1±5.6 vs 6.9±1.9). Total EAD occurrence for
Table 2 Arrhythmogenic characterization of hESC-CM clusters and rabbit PF
APD50 APD90 %EAD Triangulation STV
Control E-4031
no EAD
E-4031 Control E-4031
no EAD
E-4031 Control E-4031
no EAD
E-4031 Control E-4031
no EAD
E-4031
hESC-CM
APD90b200 ms 78±32 94±37⁎ NA 124±43 172±53⁎ NA 0% 1.6±0.2 1.9±0.5⁎ NA 0.9±0.5§ 2.9±1.7⁎ NA
n=19 n=19 n=19 n=19 n=19 n=19 n=19 n=19
hESC-CM
APD90 200–300 ms 150±23 176±34⁎ NA 237±18 311±51⁎ NA 0% 1.6±0.2 1.8±0.2⁎ NA 1.8±1.2§ 4.3±2.5⁎ NA
n=15 n=15 n=15 n=15 n=15 n=15 n=15 n=15
hESC-CM
APD90N300 ms 228±45 257±59 242±50 365±48 475±65⁎ 473±94⁎ 69% 1.6±0.2 1.9±0.3⁎ 2.0±0.3⁎ 2.7±1.5§ 3.9±2.2⁎ 6.9±1.9⁎#
n=16 n=5 n=11 n=16 n=5 n=11 11 of 16 n=16 n=5 n=11 n=11 n=4 n=7
Rabbit PF 186±28 304±39⁎ 312±33⁎ 246±30 596±103⁎ 577±94⁎ 42% 1.3±0.1‡ 2.0±0.3⁎ 1.9±0.4⁎ 1.2±0.9† 4.7±3.2⁎ 7.1±5.6⁎
n=12 n=7 n=5 n=12 n=7 n=5 5 of 12 n=12 n=7 n=5 n=10 n=6 n=4
Results based on AP recordings in 50 hESC-CM clusters and 12 rabbit PF. AP were recorded at 1 Hz during control conditions and after administration of E-4031 (1 μM). At baseline,
clusters were divided in three groups based on APD90: (1) clusters with an APD90b200 ms were not considered ventricle-like, (2) between 200 and 300 ms were considered ventricle-
like, but did not show EADs after E-4031 administration, and (3) APD90N300 ms, a majority of clusters (69%) exhibited EADs after E-4031. IKr block caused a significant increase in
APD90, triangulation, and STV. Similar results were obtained using rabbit PF. Significantly different from: ⁎ control situation, † hESC-CM APD90N300 ms, ‡ all three hESC-CM groups. §
means significantly different compared to the other two hESC-CM groups. EAD, early afterdepolarization; STV, short-term variability; APD50/APD90, action potential duration at 50/90%
repolarization; PF, Purkinje fiber.
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195Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocyteshESC-CMs and PF was 69% (11/16) and 42% (5/12), respec-
tively (Fig. 4).
ROC statistics
To analyze proarrhythmic predictive values of the
electrophysiological parameters mentioned above, receiv-
er-operated characteristics (ROC) were plotted and the area
under the curve was quantified and reported as ROC values.
APD90, triangulation, and BVR were examined. During
control conditions the values were 0.40, 0.62, and 0.66
respectively for hESC-CMs and 0.51, 0.57, and 0.46 for rabbit
PF. After administering E-4031, the values were 0.47, 0.62,
and 0.91 for hESC-CMs and 0.43, 0.49, and 0.69 for rabbit PF.
Based on these results, increased BVR on administration of E-
4031 appears a more reliable predictor of future arrhythmic
events than APD prolongation and triangulation in both
models. The ROC values for hESC-CMs were at least
equivalent to rabbit PF.
Gene expression profiling
In order to investigate themolecular substrate underlying the
different phenotypes discovered among hESC-CM clusters,
gene expression analysis was performed on clusters collected
and frozen directly after the electrophysiological measure-
ments. Based on the AP characteristics, 8 clusters with a high
beating rate (79±23) combined with a short APD90 (126±Figure 4 Data from the literature showing the incidence of
early afterdepolarizations (EADs) or torsade de pointes (TdP)
after E-4031 administration in various rabbit models. The two
bars to the right show data from the present study: in house TAP
recordings on isolated rabbit PF tissue and hESC-CM, paced at
1 Hz and administered 1 μM E-4031. c, concentration, stim f,
stimulation frequency; VM, ventricular muscle; PF, purkinje
fibers; methoxamine or phenylephrine were used to sensitize
the animals in the in vivo studies.38 ms), and 8 clusters with a low beating rate (27±20)
together with a long APD90 (314±31 ms), were selected.
Supplemental Table 1 summarizes the electrophysiological
data associated with these clusters. All genes linked to
calcium-handling except SLC81A were expressed at equal
levels in both groups, indicating a comparable level of
maturity regarding calcium handling. Five genes, HCN1 and
HCN2 (encoding subunits of If channel), GJA5 (encoding the
connexin40 gap junction protein), KCNA5 (encoding α-
subunit of IKur channel), and MYLK (encoding myosin light
chain kinase), were significantly higher expressed in the
clusters with a high beating rate and short APD (Fig. 5a). On
the contrary, six genes were expressed at significantly higher
levels in the groupwith a low beating rate and long APD; these
were KCNJ2 (encoding α-subunit of IK1 channel), SCN1B
(encoding β-subunit of INa channel), SLC81A (encoding α-
subunit of Na/Ca exchanger), ABCC9 (encoding β-subunit of
IK,ATP channel), MYH7 (encoding the β (or slow) heavy chain
subunit of cardiac myosin), and MYL2 (encoding the regula-
tory light chain associated with MYH7) (Fig. 5a). A list of all 48
genes evaluated in the Taqman array study can be found in
Supplemental Materials. Of special interest for this study
were genes encoding potassium channels underlying repolar-
ization of the AP. Fig. 5b shows the expression of theα- andβ-
subunits of the most prominently expressed repolarizing
channels in cells of the ventricles — IKs (KCNQ1, KCNE1), IKr
(KCNH2, KCNE2), and Ito (KCNA4, KCND3) — relative to the
housekeeping gene GAPDH in clusters with low beating
frequency and long APD. In Fig. 5c, immunostaining shows
localization of the hERG protein in a costaining with α-actinin
(right panel) on dissociated hESC-CMs. Additionally, electri-
cal coupling between cells was indicated by the gap junction
protein Cx43 (Fig. 5c, left panel). To relate hESC-CM
expression to expression in the adult heart we refer to a
previously published article (Xiu Qin et al., 2009).Discussion
Contemporary cell and animal models used by the pharma-
ceutical industry do not always sufficiently predict safety
and efficacy in humans, which is the major cause of high
attrition rates. Human ESCs are now regarded as an
attractive source for development of CMs. These cells may
contribute to several stages in drug discovery and safety
pharmacology (Jonsson et al., 2009). In this study, we have
evaluated basic electrophysiological characteristics and the
proarrhythmic potential of hESC-CMs with emphasis on their
applicability to contemporary models of safety screening.
One of the crucial steps in order to acquire a new model is
the ability to identify hESC-CMs with a ventricular-like
phenotype and their capacity to respond to arrhythmic
stimuli in a similar or better manner compared to contem-
porary models.
The main findings of this study are as follows: (1)
Ventricular-like clusters reproducibly could be selected
based on a beating frequency b50 bmp and an
APDN200 ms. Their more mature ventricular-like phenotype
was further supported by gene expression analysis. (2)
Occurrence of EADs on administration of the IKr blocker E-
4031 was typically observed in clusters with an APDN300 ms
while EADs were absent in clusters with an APDb300 ms.
Figure 5 (a) Taqman low-density arrays were used to analyze the gene expression in hESC-CM clusters, and differences in several
genes related to CM function were observed. High f represents clusters with a high beating rate and short APD (n=8), whereas low f
represents clusters with a low beating rate and long APD (n=8). HCN1/HCN2=If, GJA5=Cx40, KCNA5=IKur, MYLK=myosin light chain
kinase, KCNJ2= IK1, SLC8A1= INa/Ca, MYH7=myosin heavy chain, MYL2=myosin light chain, ABCC9=IK,ATP, SCN1B= INa (b) Gene
expression analysis of the α- and β-subunits of three major repolarizing K+ channels related to the housekeeping gene GAPDH in
clusters with low beating f and long APD90. (c) Immunostaining of dissociated hESC-CM clusters showing cardiac-specific α-actinin in
red and the gap junction protein Cx43 (left) or hERG (right) in green.
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triangulation. (3) Both quantitative and qualitative aspects
of the data on hESC-CMs were highly comparable to those
obtained in the rabbit PF model. The ROC data indicated that
hESC-CMs can efficiently predict arrhythmic events at least
equivalent to rabbit PF.
Over the last few years, molecular, pharmacological, and
electrophysiological studies have characterized hESC-CMs to
various extents (He et al., 2003; Mummery et al., 2003;
Sartiani et al., 2007; Satin et al., 2004; Wang et al., 2005;
Zhang et al., 2003; Caspi et al., 2009; Norstrom et al., 2006;
Kehat et al., 2002; Kehat et al., 2001; Synnergren et al.,
2007; 2008; Xu et al., 2002). Several markers expressed by
CMs are also expressed by hESC-CMs, including transcription
factors, structural proteins, ion channels, and different
junction proteins. Positive responses to α/β-adrenergic and
muscarinic stimuli suggest that the cells express surface
receptors addressing signaling pathways that activate ion
channels, membrane transporters, and myofilament proteins
(Norstrom et al., 2006; Kehat et al., 2002; Xu et al., 2002;
Xue et al., 2005). Based on their characteristics and the fact
that they are of human origin, applicability of hESC-CMs in
drug development has become an interesting target (Jonsson
et al., 2009). Various techniques have been employed to
evaluate the proarrhythmic predictive potential of hESC-
CMs. Multielectrode arrays (MEAs) are used to record
extracellular electrical activity of an excitable multicellular
preparation, and they can be applied to hESC-CM clusters.
Although this technique may give an idea of AP prolongation,
its ability to detect proarrhythmic events, such as formation
of EADs, is limited. Still, it is a valuable tool which has
successfully been used by several groups (Satin et al., 2004;
Caspi et al., 2009; Kehat et al., 2002; Braam et al., 2010;
Reppel et al., 2005), and it may especially be of use in studies
of cardiac conduction. Using the MEA system, it has been
shown that hESC-CM clusters respond to a variety of drugs
affecting different ion currents (Caspi et al., 2009; Braam
et al., 2010). Intracellular recordings using either patch-
clamp or sharp microelectrodes do, on the other hand,
provide information on arrhythmic events. Even though
several studies have identified electrophysiological charac-
teristics of hESC-CMs, standardization and quantification of
arrhythmic endpoints, and comparison to contemporary
models are generally lacking.
Standardization
Comparable to previously published data (He et al., 2003;
Mummery et al., 2003), we report APs corresponding to those
of embryonic ventricular-like, atrial-like, and nodal-like
CMs. We further observed that spontaneous beating fre-
quency allows an initial selection towards the often
preferred ventricular-like phenotype. hESC-CM clusters
with a beating frequency N50 bpm generally (26/27)
displayed an APD90b300 ms; thus 50 bpm could be used as
a cutoff point to discriminate clusters with a nonventricular-
like phenotype. For clusters with a beating rate b50 bpm,
19/23 showed APD90N200 ms, and 15/23 APD90N300 ms
(Fig. 2). These results correspond well with previous reports,
where cells with ventricular-like APs had an average of
47 bpm (He et al., 2003), 45 resp 33 bpm (different cell lines)
(Zhang et al., 2009), or 36 bpm (Mummery et al., 2003). Thedistinction between atrial- and nodal-like cells is not
perfectly clear, and should be interpreted with caution.
Nevertheless, differences in AP upstroke velocity and AP
amplitude appeared to be useful parameters that allowed
separation of atrial-like clusters from nodal-like clusters.
Using the described selection criteria, we were able to
efficiently select ventricular-like clusters sensitive to a
commonly accepted proarrhythmic compound like E-4031.
Cells with an atrial- or nodal-like phenotype can be useful for
other types of studies, for example, to test new compounds
against atrial fibrillation. When cultures containing only the
ventricular-like phenotype are demanded, more sophisticat-
ed differentiation protocols are needed. Coculturing with a
visceral endoderm-like cell line (END-2) proved to be
effective in generating cultures with N85% ventricular-like
cells (Mummery et al., 2003).
Quantification of arrhythmic endpoints
Many of the parameters used to assess the proarrhythmic
potential of a compound are more or less subject to
discussion with respect to their individual predictive
capacity (Thomsen et al., 2004; Belardinelli et al., 2003;
Thomsen et al., 2006). This also includes the role of APD
itself in predicting arrhythmic events. AP prolongation as
such may not be proarrhythmic at all, and has even been
suggested to act in an antiarrhythmic manner (Hondeghem et
al., 2001). However, both spatial and temporal variability in
APD may be an additional parameter that contributes to the
development of EADs on a cellular level (Jonsson et al., 2009;
Hondeghem et al., 2001; Belardinelli et al., 2003). Honde-
ghem elegantly developed the TRIaD scoring system for a
more complete assessment of a compounds’ proarrhythmic
effect (Hondeghem, 2005). Out of the four components of
TRIaD, we analyzed two in this study. The third (instability)
was replaced by STV which is a quantifying parameter that
takes the consecutiveness of the beat into account. The
fourth (spatial dispersion of repolarization) is not accessible
in hESC-CM clusters. Given the discussion about the
predictive value of individual parameters, we believe that
it is important to use multiple parameters when evaluating
the effects of compounds with unknown effects. By using E-
4031 to block IKr we quantified the final endpoint of cellular
arrhythmias: EADs, the cellular event underlying the onset of
torsade de pointes (TdP) arrhythmias in vivo (Belardinelli
et al., 2003; Schreiner et al., 2004). The data in the present
study show that when a beating frequency lower than 50 bpm
and an APD90 longer than 300 ms where used as selection
criteria for the hESC-CMs, EADs were absent under control
conditions but occurred in 69% of the clusters after
application of E-4031. Importantly, prior to EADs, a
significant increase in triangulation and STV was measured
and reverse frequency dependence could be demonstrated.
Although triangulation could not predict future arrhythmic
events in this study, STV could.
Comparison with an existing model
The rabbit PF is a frequently used and well-validated
model for testing arrhythmic effects of new compounds,
and it has proved to be a more suitable model for
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than PF from other species (Thomsen et al., 2006;
Dumotier et al., 1999; Lu et al., 2001). PF have also
been reported to be more sensitive to drug-induced long
APD and EADs than papillary muscle (Abrahamsson et al.,
1996) or ventricular tissue (Persson et al., 2007). E-4031,
which is commonly used in different rabbit models (Persson
et al., 2007; Bril et al., 1996; Hara et al., 1998; Liu et al.,
2005; Michael et al., 2007; Studenik et al., 2001), was in
the present study used to provoke arrhythmic events
through the formation of EADs (Fig. 4). Although always
sensitive to IKr block, the incidence of EADs or TdP after E-
4031 administration in various rabbit models is diverse. The
variability (from 32 to 90%) between the different studies
is likely due to differences in drug concentration and
pacing frequency but it is still clear that our hESC-CM
results fit well in this literature overview. The fact that
APD90, triangulation, and STV are larger in hESC-CM at
baseline as compared to rabbit PF could be related to
lower and more heterogeneous intercellular coupling
present in hESC-CM clusters. It is known that multicellular
preparations, including whole hearts, will reduce the
intrinsic differences between cells (Anyukhovsky et al.,
1999). The ROC data suggest that when using STV as a
predictive marker for subsequent arrhythmic events, hESC-
CMs represent a highly relevant model.Gene expression analysis
To further investigate the mechanisms underlying the
different electrophysiological phenotypes observed among
the hESC-CMs, clusters were grouped based on beating
frequency and APD, and gene expression analysis was
performed. As expected, the clusters with a higher beating
frequency expressed increased levels of HCN1 and HCN2,
encoding subunits of pacemaker channels (If) that drive the
spontaneous activity of CMs. These clusters also had lower
RNA expression of KCNJ2 (IK1), which contributes to a less
stable resting membrane potential. The same clusters
showed increased expression of GJA5, the gene encoding
connexin40, a gap junction protein mainly expressed in atrial
and nodal CMs. The shorter APD in these clusters is supported
by the observation that KCNA5 (IKur) was expressed at higher
levels in these cells than in the other group. IKur is an atrial
specific ion current that is involved in the repolarization of
atrial CMs. The clusters with a lower beating rate and longer
APD expressed higher levels of MYH7, MYL2, KCNJ2, and
SCN1B. The first two genes are responsible for proteins that
form the contractile machinery and, tentatively, their higher
expression may result in a more mature phenotype. The last
two genes encode the α-subunit of the IK1 current and the β-
subunit of the cardiac sodium channel, respectively.
Elevated expression of both of these genes fits well to the
ventricular-like phenotype of those clusters. These results
support our selection criteria for hESC-CMs with a ventric-
ular-like phenotype, and may also serve as a guideline in
future work of directing differentiation of hESC into the
preferred phenotype.
The gene expression analysis additionally showed expres-
sion patterns for the major repolarizing currents (IKs, IKr and
Ito) in ventricular cells. For all three channels, the channelforming α-subunit was higher expressed than the regulatory
β-subunit. During embryonic development, the α-subunits
are evenly expressed throughout the heart, and regional
differences in channel activity are thought to be the result of
varying β-subunit expression (Franco et al., 2001). The lower
β-subunit expression may help to explain why the electro-
physiological parameters of hESC-CMs are not yet fully
mature. Staining of Cx43, the main gap junction protein in
ventricular CMs, showed coupling between cells which is of
outmost importance in a multicellular preparation.
In summary, the data presented in this study support the
use of hESC-CMs for safety pharmacology testing. Since the
access to native human CMs for research purposes is very
limited, and even when accessed, these cells appear short
lived and difficult to handle in vitro, hESC-CMs represent an
attractive alternative human cell source. Being cells that
express all ion channels and their subunits, plus other
receptors and signaling pathways found in human CMs,
hESC-CMs are far more complete than contemporary over-
expression systems where only one, or very few proteins, can
be expressed simultaneously. Although they do not represent
a complete organism, the use of hESC-CM clusters can
contribute to a reduction of the number of experimental
animals needed for tissue extraction. In addition, they will
allow for further development of improved screening
methods, thereby aiding the process of reducing and refining
tests. Taken together, the results presented in this study
indicate several benefits for the use of hESC-CMs in future
safety pharmacology, and warrant further validation of the
model.
Materials and methods
hESC differentiation
Generation of CM clusters was preformed as described
previously (Synnergren et al., 2008) using the hESC line
SA002 (Cellartis AB, Göteborg). Spontaneously contracting
clusters were identified by visual inspection and isolated
from the cultures by mechanical dissection. All experiments
were performed after 42–56 days of differentiation. hESC-
CM clusters were maintained in DMEM supplemented with
glutamax and 1% PEST, 1% NEAA, 0.1 mM β-mercaptoethanol,
and 20% heat-inactivated FBS. The clusters were transferred
to coverslips at least 4 days prior to experiments.
Isolation of rabbit PF
Twelve Male New Zealand White rabbits (body weight 2.5 to
3.5 kg) were anesthetized with pentobarbital sodium
(60 mg/kg iv). After excision, the heart was placed in
potassium-enriched Tyrode's solution and the right ventric-
ular anterior papillary muscle with Purkinje fibers running
across its base was dissected. The tissue was mounted in a
2 ml organ bath, superfused with Tyrode's solution, and left
to stabilize for approximately 2 h before the experimental
protocol was initiated. The investigation conforms with the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996), and was approved by the Swedish
ethics review board (EA:100505).
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Transmembrane action potentials were recorded using a
sharp microelectrode filled with 3 M KCl. Steady-state
recordings of APs at electric field stimulation of 1 or 2 Hz
(pulses 2.0 ms in duration and 100% above threshold in
intensity) were made. All calculations were made on the
average of 10 (consecutive) APs, except for short-term
variability (based on 30 consecutive beats) which was
calculated using the formula STV=Σ│Dn+1−Dn│/[30√2]
where D represents APD90 (Thomsen et al., 2004). Pacing
was occasionally interrupted by brief pauses during control
conditions and after E-4031 administration. The bath was
continuously perfused with Tyrode's solution and kept at
37 °C. All drugs and solutions are described in the
supplemental materials. Recordings were made at the
University Medical Center Utrecht (The Netherlands) and at
AstraZeneca (Sweden) using 9 independently generated
batches of differentiated cells.
RNA isolation and Taqman analysis
Following TAP recordings, hESC-CM clusters were collected
and snap-frozen in liquid nitrogen and stored at −80 °C. Total
RNA was isolated using the RNeasy Micro Plus kit (Qiagen).
cDNA was synthesized from 180 ng of RNA using Superscript III
(Invitrogen). The 384-well microfluidic cards (7900HT Fast
Real-Time PCR System) from Applied Biosystems were used
for transcription analysis of 48 genes (see Supplemental Table
2). GAPDH and RPLP0 were used as housekeeping genes.
Calculations and statistical analysis
All values are presented as mean±SD (unless stated other-
wise). See supplemental materials for details. Pb0.05 was
considered as significant.
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